Avitia
PrivateLast Round
Seed
Feb 27, 2025
Total Funding Raised
$5M
Company Overview
Avitia is a healthtech company that provides an AI-powered molecular testing platform designed to accelerate cancer diagnostics and targeted treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avitia Comparables
Compare Avitia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GeneSilico | 82% | |
| Hedera Dx | 80% | |
| SeqOne | 77% | |
Avitia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 27, 2025 |
Key People
Founding team and executive leadership
Avitia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| PacBridge Capital Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 2, 2025
Partnered with Genoscience to expand cancer testing access to 50+ locations.
Avitia Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Avitia's valuation, stock price, and market status.